KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash & Equivalents (2016 - 2026)

Gilead Sciences filings provide 17 years of Cash & Equivalents readings, the most recent being $7.6 billion for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 24.29% to $7.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 billion, a 24.29% decrease, with the full-year FY2025 number at $7.6 billion, down 24.29% from a year prior.
  • Cash & Equivalents hit $7.6 billion in Q4 2025 for Gilead Sciences, up from $7.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $10.0 billion in Q4 2024 to a low of $2.8 billion in Q2 2024.
  • Median Cash & Equivalents over the past 5 years was $5.1 billion (2024), compared with a mean of $5.5 billion.
  • Biggest five-year swings in Cash & Equivalents: plummeted 66.15% in 2021 and later skyrocketed 85.57% in 2025.
  • Gilead Sciences' Cash & Equivalents stood at $5.3 billion in 2021, then increased by 1.39% to $5.4 billion in 2022, then increased by 12.44% to $6.1 billion in 2023, then surged by 64.19% to $10.0 billion in 2024, then fell by 24.29% to $7.6 billion in 2025.
  • The last three reported values for Cash & Equivalents were $7.6 billion (Q4 2025), $7.3 billion (Q3 2025), and $5.1 billion (Q2 2025) per Business Quant data.